IRIS
ZANGHI', Mariangela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.745
NA - Nord America 2.164
AS - Asia 1.064
SA - Sud America 278
Continente sconosciuto - Info sul continente non disponibili 37
AF - Africa 32
OC - Oceania 1
Totale 6.321
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.127
RU - Federazione Russa 1.387
SG - Singapore 431
CN - Cina 355
SE - Svezia 313
IE - Irlanda 289
BR - Brasile 249
IT - Italia 229
HK - Hong Kong 116
DE - Germania 106
FR - Francia 95
UA - Ucraina 87
GB - Regno Unito 68
PL - Polonia 58
FI - Finlandia 50
VN - Vietnam 47
IN - India 33
BE - Belgio 23
CA - Canada 15
AR - Argentina 12
ZA - Sudafrica 12
MX - Messico 9
BD - Bangladesh 8
PK - Pakistan 8
CO - Colombia 7
IQ - Iraq 7
JP - Giappone 7
NL - Olanda 7
MA - Marocco 6
TR - Turchia 6
ES - Italia 5
NO - Norvegia 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
ET - Etiopia 4
JO - Giordania 4
PH - Filippine 4
SA - Arabia Saudita 4
VE - Venezuela 4
DZ - Algeria 3
ID - Indonesia 3
IR - Iran 3
JM - Giamaica 3
LT - Lituania 3
MY - Malesia 3
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
EC - Ecuador 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
RO - Romania 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AT - Austria 1
BH - Bahrain 1
BS - Bahamas 1
BZ - Belize 1
CI - Costa d'Avorio 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
TN - Tunisia 1
Totale 6.286
Salva come PNG Salva come JPEG
Città #
Moscow 382
Dublin 287
Ashburn 280
Singapore 243
Chandler 212
Dallas 192
Nyköping 169
Jacksonville 166
Beijing 129
San Jose 118
Hong Kong 116
Ann Arbor 72
The Dalles 70
Council Bluffs 61
New York 58
Warsaw 56
Los Angeles 48
Dearborn 47
Messina 42
Medford 40
Princeton 40
Cambridge 39
Des Moines 35
Lauterbourg 35
Boardman 29
Munich 27
Brussels 23
São Paulo 23
Woodbridge 23
Buffalo 21
Tianjin 20
Lancaster 19
Ho Chi Minh City 17
San Mateo 17
Jinan 15
Wilmington 14
Chicago 13
Pune 12
Frankfurt am Main 11
Hebei 11
Houston 10
Orem 10
Santa Clara 10
Zhengzhou 10
Brooklyn 9
Guangzhou 9
Nanjing 9
Rio de Janeiro 9
Taizhou 9
Denver 8
Hanoi 8
Johannesburg 8
Shenyang 8
Turku 8
London 7
Montreal 7
Seattle 7
Stockholm 7
Belo Horizonte 6
Chennai 6
Columbus 6
Düsseldorf 6
Manchester 6
Nanchang 6
Ningbo 6
Redondo Beach 6
San Francisco 6
Amsterdam 5
Brasília 5
Haiphong 5
Hangzhou 5
Leawood 5
Monmouth Junction 5
Mumbai 5
Tokyo 5
Addis Ababa 4
Amman 4
Atlanta 4
Auburn Hills 4
Augusta 4
Boston 4
Jiaxing 4
Las Vegas 4
Medellín 4
Oslo 4
Phoenix 4
Ribeirão Preto 4
Rome 4
Tashkent 4
Barnet 3
Belém 3
Bremen 3
Brockport 3
Changsha 3
Cuiabá 3
Curitiba 3
Duque de Caxias 3
Genova 3
Goiânia 3
Guarulhos 3
Totale 3.568
Salva come PNG Salva come JPEG
Nome #
Linfoscintigrafia ascellare preoperatoria nel cancro della mammella. 327
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 246
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 227
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 212
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 206
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 188
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 186
INCIDENZA DELL'ONCOTIPO POLMONARE NELLO STESSO TERRITORIO IN TRIENNI DIFFERENTI- 1983/84/85 E 1993/94/95. Eur. Jour. of Oncology Vol. 2, n° 4, 1997. 182
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 177
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 177
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 175
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 168
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 167
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 166
Second line chemoterapy in patients with metastatic colorectal cancer(MCRC):our experience 165
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 159
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 158
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 158
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. 153
Incidenza dell’oncotipo polmonare nello stesso territorio in trienni differenti 1983/84/85 e 1993/94/95. 153
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 151
Dati preliminari sulla caratterizzazione molecolare dei casi di melanoma familiare di origine siciliana. 150
IL-33/IL-31 axis: A new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity? 150
Dati preliminari sulla caratterizzazione molecolare dei casi di melanoma familiare di origine siciliana. 149
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 149
Dati preliminari sulla caratterizzazione molecolare dei casi di melanoma familiare di origine siciliana. 148
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 148
Impact of single-nucleotide polymorphisms in genes coding for folate pathway enzymes on efficacy/toxicity of gemcitabine and pemetrexed based therapy in advanced non small cell lung cancer (NSCLC): new prospectives for old markers. 142
NSCLC and HER2: between lights and shadows 134
Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. 128
LINFOSCINTIGRAFIA ASCELLARE PREOPERATORIA DEL CANCRO DELLA MAMMELLA. Acta Oncologica - Voi. XVI – n. 1, 1995. 127
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 126
OUR EXPERIENCE ON THE EFFECTS OF TAMOXIFEN ON BLOOD COAGULATION IN PATIENTS OPERATED FOR BREAST CANCER Folia Oncologica vol.XIV-n.2-3 (Aprile-Settembre)-1991 122
Molecular and clinical analysis of predictive biomarkers to anti-EGFR inhibitors in metastatic colorectal cancer (mCRC): Interaction among early tumor shrinkage, skin toxicities, and RAS status. 121
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 116
PHASE II STUDY OF LIPOSOMAL DOXORUBICIN AND GEMCYTABINE IN THE TREATMENT OF RECURRENT OVARIAN CANCER 113
Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (MO) unresectable head and neck squamous cell carcinoma: a dose escalation study 111
Safety of Zoledronic acid in bone metastatic breast cancer patients: A retrospective analysis. 102
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 99
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 63
null 22
Totale 6.321
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.320
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.320
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022328 0 57 6 10 6 1 25 9 3 86 40 85
2022/2023879 70 93 39 68 65 77 7 69 363 0 20 8
2023/2024227 20 42 7 24 12 81 14 14 0 4 0 9
2024/2025793 6 7 14 52 27 29 7 145 210 55 68 173
2025/20262.827 164 147 185 135 226 654 374 388 384 97 36 37
2026/202799 27 72 0 0 0 0 0 0 0 0 0 0
Totale 6.321